Posted on March 14, 2023


In the February 2023 issue of Evidence-Based GI, the title of the article on dupilumab incorrectly referred to it as “an anti-interleukin-4/12 monoclonal antibody,” and not an anti-interleukin-4/13 monoclonal antibody. The article title has been corrected in the published article to: “Dupilumab, an IgG4 Monoclonal Antibody for Eosinophilic Esophagitis: Revising the Treatment Paradigm.”

Please use the below citation when referencing the article:

Kamal A, Schoenfeld P. Dupilumab, an IgG4 monoclonal antibody for eosinophilic esophagitis: Revising the treatment paradigm. Evidence-Based GI. Published February 21, 2023. Updated March 14, 2023.

The authors apologize for this error.


Correction PDF